| Followers | 15 |
| Posts | 571 |
| Boards Moderated | 1 |
| Alias Born | 08/04/2011 |
Wednesday, July 17, 2019 12:03:35 PM
Dawson initiates coverage.
With a $1.00 PT
https://www.biotuesdays.com/briefs/2019/7/2/dawson-james-starts-isoray-at-buy-pt-1
I haven't looked at this in ten years!
Seems like they're still treading water (sales-wise).
Have to check out this new Blu thing. While I smoking a Blu!
Sales and marketing expenses were $645,000 to generate $1.9 million in sales. Maybe they're investing for the future..
"This fiscal third quarter of 2019 marks our eighth consecutive quarter of double-digit revenue growth with sales growing 22% over the year-ago quarter. Once again, the key driver of growth this quarter was IsoRay’s core prostate brachytherapy revenue which increased 30% versus the fiscal third quarter of 2018."
"We continue to estimate that Blu Build expands our domestic prostate cancer opportunity by $25 million to approximately $100 million."
https://seekingalpha.com/article/4262241-isoray-inc-isr-ceo-lori-woods-q3-2019-results-earnings-call-transcript?part=single
With a $1.00 PT
https://www.biotuesdays.com/briefs/2019/7/2/dawson-james-starts-isoray-at-buy-pt-1
I haven't looked at this in ten years!
Seems like they're still treading water (sales-wise).
Have to check out this new Blu thing. While I smoking a Blu!
Sales and marketing expenses were $645,000 to generate $1.9 million in sales. Maybe they're investing for the future..
"This fiscal third quarter of 2019 marks our eighth consecutive quarter of double-digit revenue growth with sales growing 22% over the year-ago quarter. Once again, the key driver of growth this quarter was IsoRay’s core prostate brachytherapy revenue which increased 30% versus the fiscal third quarter of 2018."
"We continue to estimate that Blu Build expands our domestic prostate cancer opportunity by $25 million to approximately $100 million."
https://seekingalpha.com/article/4262241-isoray-inc-isr-ceo-lori-woods-q3-2019-results-earnings-call-transcript?part=single
Recent CATX News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/12/2026 04:47:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:13:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:10:44 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results • GlobeNewswire Inc. • 05/11/2026 08:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:43:03 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:23 PM
- Perspective Therapeutics to Provide Several Upcoming Corporate Updates • GlobeNewswire Inc. • 04/24/2026 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/20/2026 10:05:00 AM
- Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 04/20/2026 10:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 08:10:52 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 08:10:05 PM
- Perspective Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 04/02/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:16:31 PM
- Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 03/17/2026 08:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:12:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:10:36 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results • GlobeNewswire Inc. • 03/16/2026 08:07:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 03/11/2026 12:36:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:38:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:38:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:37:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:37:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:35:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:34:56 PM
